Replacement of highly conserved Leucine with Phenylalanine (p.L378F) in PIGO causes development clinical findings such as epileptic encephalopathy, developmental delay, hypotonia, ataxia, and hyperphosphatemia; this is a novel variant that was reported by Aguech et al. [26]. This evidence concerns the gene PIGO and Ataxia.